Generic Colcrys Availability

Last updated on Apr 10, 2025.

Colcrys is a brand name of colchicine, approved by the FDA in the following formulation(s):

COLCRYS (colchicine - tablet;oral)

Manufacturer: TAKEDA PHARMS USA
Approval date: July 29, 2009
Strength(s): 0.6MG (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Colcrys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Patent 7,601,758
Issued: October 13, 2009
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Methods for treating gout flares comprising concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.
Patent expiration dates:
- February 10, 2029
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 7,619,004
Issued: November 17, 2009
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.
Patent expiration dates:
- December 3, 2028
  ✓
  Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
Methods for concomitant administration of colchicine and a second active agent
Patent 7,820,681
Issued: October 26, 2010
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- February 17, 2029
  ✓
  Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
Methods for concomitant administration of colchicine and a second active agent
Patent 7,906,519
Issued: March 15, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): AR Holding Company, Inc. (Wilmington, DE)
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- February 17, 2029
  ✓
  Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
Methods for concomitant administration of colchicine and a second active agent
Patent 7,915,269
Issued: March 29, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): AR Holding Company, Inc. (Wilmington, DE)
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- February 17, 2029
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 7,935,731
Issued: May 3, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
Patent expiration dates:
- December 3, 2028
  ✓
  Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
Colchicine compositions and methods
Patent 7,964,647
Issued: June 21, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Methods for concomitant administration of colchicine and a second active agent
Patent 7,964,648
Issued: June 21, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
Colchicine compositions and methods
Patent 7,981,938
Issued: July 19, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 8,093,296
Issued: January 10, 2012
Inventor(s): Davis Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Methods for concomitant administration of colchicine and a second active agent
Patent 8,093,297
Issued: January 10, 2012
Inventor(s): Davis Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 8,093,298
Issued: January 10, 2012
Inventor(s): Davis Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 8,097,655
Issued: January 17, 2012
Inventor(s): Davis Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
Colchicine compositions and methods
Patent 8,415,395
Issued: April 9, 2013
Inventor(s): Davis Matthew W. & Feng Hengsheng
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Colchine compositions and methods
Patent 8,415,396
Issued: April 9, 2013
Inventor(s): Davis Matthew W. & Feng Hengsheng
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
Patent expiration dates:
- October 6, 2028
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Methods for concomitant administration of colchicine and a second active agent
Patent 8,440,721
Issued: May 14, 2013
Inventor(s): Davis Matthew W.
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- February 17, 2029
  ✓
  Patent use: METHOD OF TREATING GOUT FLARES
Methods for concomitant administration of colchicine and a second active agent
Patent 8,440,722
Issued: May 14, 2013
Inventor(s): Davis Matthew W.
Assignee(s): Takeda Pharamceuticals U.S.A., Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Patent expiration dates:
- February 17, 2029
  ✓
  Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

More about Colcrys (colchicine)

Related treatment guides

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

7.8 / 10

24 Reviews